Birgit S. Geurts

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects

N. de Vries, Joris van de Haar, Vivien Veninga et al. · Nature · 2023 · 265 citations · Full text

A pan-cancer analysis of the microbiome in metastatic cancer

Thomas Battaglia, Iris Mimpen, Joleen J.H. Traets et al. · Cell · 2024 · 162 citations · Full text

Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol

Karlijn Verkerk, Birgit S. Geurts, Laurien J. Zeverijn et al. · The Lancet Regional Health - Europe · 2024 · 26 citations · Full text

The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP)

Soemeya F. Haj Mohammad, Hans Timmer, Laurien J. Zeverijn et al. · Acta Oncologica · 2024 · 20 citations · Full text

Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin<scp>D‐CDK4</scp>/6 pathway alterations in the Dutch<scp>DRUP</scp>and Australian<scp>MoST</scp>trials

Laurien J. Zeverijn, Eleonora J. Looze, Subotheni Thavaneswaran et al. · International Journal of Cancer · 2023 · 19 citations · Full text